Therapeutic targeting of EGFR-activated metabolic pathways in glioblastoma

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Glioblastoma (GBM) exhibits significant histological heterogeneity, aggressive invasion, and poor treatment response, making it a highly lethal human cancer.
• Epidermal growth factor receptor (EGFR) plays a key role in GBM progression, but current therapies, including EGFR-targeted drugs, have shown limited efficacy.
• Current research focuses on inhibiting downstream metabolic pathways activated by EGFR and key phosphorylated kinases involved in GBM.

Purpose of the Study:

• To review the major EGFR-activated downstream metabolic pathways in GBM: PI3K/AKT/mTOR and RAS/RAF/MAPK.
• To discuss key phosphorylated kinase alterations within these pathways in GBM.
• To evaluate pharmacological progress and potential therapeutics targeting PI3K and RAS signaling pathways from preclinical research to clinical trials.

Main Methods:

• Literature review of EGFR-activated pathways in GBM.
• Analysis of PI3K/AKT/mTOR and RAS/RAF/MAPK pathway alterations.
• Discussion of current and emerging therapeutic strategies targeting these pathways.

Main Results:

• Identification of PI3K/AKT/mTOR and RAS/RAF/MAPK as critical EGFR-driven pathways in GBM.
• Highlighting specific kinase alterations within these pathways that drive GBM.
• Summarizing the status of inhibitors and therapeutics targeting these signaling cascades.

Conclusions:

• Clinical progress in GBM treatment is hindered by acquired resistance, tumor heterogeneity, pathway complexity, and blood-brain barrier (BBB) penetration challenges.
• Future therapeutic approaches will likely involve rational combinatorial regimens and patient stratification based on molecular phenotypes.
• Deeper understanding of GBM's genetic and molecular pathways is crucial for developing novel and effective treatments.